Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.
Roche, Teva and Mylan are the top 3 of Capecitabine, with about 87% market shares.
The global Capecitabine market was valued at US$ 1021.8 million in 2020 and is expected to reach US$ 1001.8 million by the end of 2029, growing at a CAGR of -0.4% during 2021-2029.
This report focuses on Capecitabine volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Capecitabine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Capecitabine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2029. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
500 mg
150 mg
Segment by Application
Breast Cancer
Colorectal Cancer
Stomach Cancer
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
1 Capecitabine Market Overview
1.1 Product Overview and Scope of Capecitabine
1.2 Capecitabine Segment by Type
1.2.1 Global Capecitabine Sales Growth Rate Comparison by Type (2021-2029)
1.2.2 500 mg
1.2.3 150 mg
1.3 Capecitabine Segment by Application
1.3.1 Global Capecitabine Sales Comparison by Application: (2021-2029)
1.3.2 Breast Cancer
1.3.3 Colorectal Cancer
1.3.4 Stomach Cancer
1.4 Global Capecitabine Market Size Estimates and Forecasts
1.4.1 Global Capecitabine Revenue 2016-2029
1.4.2 Global Capecitabine Sales 2016-2029
1.4.3 Capecitabine Market Size by Region: 2016 Versus 2021 Versus 2029
2 Capecitabine Market Competition by Manufacturers
2.1 Global Capecitabine Sales Market Share by Manufacturers (2016-2021)
2.2 Global Capecitabine Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Capecitabine Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Capecitabine Manufacturing Sites, Area Served, Product Type
2.5 Capecitabine Market Competitive Situation and Trends
2.5.1 Capecitabine Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Capecitabine Players Market Share by Revenue
2.5.3 Global Capecitabine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Capecitabine Retrospective Market Scenario by Region
3.1 Global Capecitabine Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Capecitabine Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Capecitabine Market Facts & Figures by Country
3.3.1 North America Capecitabine Sales by Country
3.3.2 North America Capecitabine Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Capecitabine Market Facts & Figures by Country
3.4.1 Europe Capecitabine Sales by Country
3.4.2 Europe Capecitabine Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Capecitabine Market Facts & Figures by Region
3.5.1 Asia Pacific Capecitabine Sales by Region
3.5.2 Asia Pacific Capecitabine Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Capecitabine Market Facts & Figures by Country
3.6.1 Latin America Capecitabine Sales by Country
3.6.2 Latin America Capecitabine Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Capecitabine Market Facts & Figures by Country
3.7.1 Middle East and Africa Capecitabine Sales by Country
3.7.2 Middle East and Africa Capecitabine Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Capecitabine Historic Market Analysis by Type
4.1 Global Capecitabine Sales Market Share by Type (2016-2021)
4.2 Global Capecitabine Revenue Market Share by Type (2016-2021)
4.3 Global Capecitabine Price by Type (2016-2021)
5 Global Capecitabine Historic Market Analysis by Application
5.1 Global Capecitabine Sales Market Share by Application (2016-2021)
5.2 Global Capecitabine Revenue Market Share by Application (2016-2021)
5.3 Global Capecitabine Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Capecitabine Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Roche Capecitabine Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Teva
6.2.1 Teva Corporation Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Capecitabine Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Teva Capecitabine Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 Mylan
6.3.1 Mylan Corporation Information
6.3.2 Mylan Description and Business Overview
6.3.3 Mylan Capecitabine Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Mylan Capecitabine Product Portfolio
6.3.5 Mylan Recent Developments/Updates
6.4 Hikma
6.4.1 Hikma Corporation Information
6.4.2 Hikma Description and Business Overview
6.4.3 Hikma Capecitabine Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Hikma Capecitabine Product Portfolio
6.4.5 Hikma Recent Developments/Updates
6.5 Hengrui Medicine
6.5.1 Hengrui Medicine Corporation Information
6.5.2 Hengrui Medicine Description and Business Overview
6.5.3 Hengrui Medicine Capecitabine Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Hengrui Medicine Capecitabine Product Portfolio
6.5.5 Hengrui Medicine Recent Developments/Updates
6.6 Cipla
6.6.1 Cipla Corporation Information
6.6.2 Cipla Description and Business Overview
6.6.3 Cipla Capecitabine Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Cipla Capecitabine Product Portfolio
6.6.5 Cipla Recent Developments/Updates
6.7 Reliance Group
6.6.1 Reliance Group Corporation Information
6.6.2 Reliance Group Description and Business Overview
6.6.3 Reliance Group Capecitabine Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Reliance Group Capecitabine Product Portfolio
6.7.5 Reliance Group Recent Developments/Updates
6.8 Hetero
6.8.1 Hetero Corporation Information
6.8.2 Hetero Description and Business Overview
6.8.3 Hetero Capecitabine Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Hetero Capecitabine Product Portfolio
6.8.5 Hetero Recent Developments/Updates
7 Capecitabine Manufacturing Cost Analysis
7.1 Capecitabine Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Capecitabine
7.4 Capecitabine Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Capecitabine Distributors List
8.3 Capecitabine Customers
9 Capecitabine Market Dynamics
9.1 Capecitabine Industry Trends
9.2 Capecitabine Growth Drivers
9.3 Capecitabine Market Challenges
9.4 Capecitabine Market Restraints
10 Global Market Forecast
10.1 Capecitabine Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Capecitabine by Type (2022-2029)
10.1.2 Global Forecasted Revenue of Capecitabine by Type (2022-2029)
10.2 Capecitabine Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Capecitabine by Application (2022-2029)
10.2.2 Global Forecasted Revenue of Capecitabine by Application (2022-2029)
10.3 Capecitabine Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Capecitabine by Region (2022-2029)
10.3.2 Global Forecasted Revenue of Capecitabine by Region (2022-2029)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Capecitabine Sales (Kg) Growth Rate Comparison by Type (2021-2029)
Table 2. Global Capecitabine Sales (Kg) Comparison by Application (2021-2029)
Table 3. Global Capecitabine Market Size by Region (US$ Million) (2016 VS 2021 VS 2029)
Table 4. Key Manufacturers Capecitabine Covered in This Study
Table 5. Global Capecitabine Sales (Kg) of Key Manufacturers (2016-2021)
Table 6. Global Capecitabine Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Capecitabine Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Capecitabine Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Capecitabine Average Price (USD/g) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Capecitabine Manufacturing Sites and Area Served
Table 11. Manufacturers Capecitabine Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Capecitabine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Capecitabine as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Capecitabine Sales by Region (2016-2021) & (Kg)
Table 16. Global Capecitabine Sales Market Share by Region (2016-2021)
Table 17. Global Capecitabine Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Capecitabine Sales by Country (2016-2021) & (Kg)
Table 19. North America Capecitabine Sales Market Share by Country (2016-2021)
Table 20. North America Capecitabine Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Capecitabine Revenue Market Share by Country (2016-2021)
Table 22. Europe Capecitabine Sales by Country (2016-2021) & (Kg)
Table 23. Europe Capecitabine Sales Market Share by Country (2016-2021)
Table 24. Europe Capecitabine Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Capecitabine Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Capecitabine Sales by Region (2016-2021) & (Kg)
Table 27. Asia Pacific Capecitabine Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Capecitabine Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Capecitabine Revenue Market Share by Region (2016-2021)
Table 30. Latin America Capecitabine Sales by Country (2016-2021) & (Kg)
Table 31. Latin America Capecitabine Sales Market Share by Country (2016-2021)
Table 32. Latin America Capecitabine Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Capecitabine Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Capecitabine Sales by Country (2016-2021) & (Kg)
Table 35. Middle East and Africa Capecitabine Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Capecitabine Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Capecitabine Revenue Market Share by Country (2016-2021)
Table 38. Global Capecitabine Sales (Kg) by Type (2016-2021)
Table 39. Global Capecitabine Sales Market Share by Type (2016-2021)
Table 40. Global Capecitabine Revenue (Million US$) by Type (2016-2021)
Table 41. Global Capecitabine Revenue Share by Type (2016-2021)
Table 42. Global Capecitabine Price (USD/g) by Type (2016-2021)
Table 43. Global Capecitabine Sales (Kg) by Application (2016-2021)
Table 44. Global Capecitabine Sales Market Share by Application (2016-2021)
Table 45. Global Capecitabine Revenue (Million US$) by Application (2016-2021)
Table 46. Global Capecitabine Revenue Share by Application (2016-2021)
Table 47. Global Capecitabine Price (USD/g) by Application (2016-2021)
Table 48. Roche Corporation Information
Table 49. Roche Description and Business Overview
Table 50. Roche Capecitabine Sales (Kg), Revenue (Million US$), Price (USD/g) and Gross Margin (2016-2021)
Table 51. Roche Capecitabine Product
Table 52. Roche Recent Developments/Updates
Table 53. Teva Corporation Information
Table 54. Teva Description and Business Overview
Table 55. Teva Capecitabine Sales (Kg), Revenue (Million US$), Price (USD/g) and Gross Margin (2016-2021)
Table 56. Teva Capecitabine Product
Table 57. Teva Recent Developments/Updates
Table 58. Mylan Corporation Information
Table 59. Mylan Description and Business Overview
Table 60. Mylan Capecitabine Sales (Kg), Revenue (Million US$), Price (USD/g) and Gross Margin (2016-2021)
Table 61. Mylan Capecitabine Product
Table 62. Mylan Recent Developments/Updates
Table 63. Hikma Corporation Information
Table 64. Hikma Description and Business Overview
Table 65. Hikma Capecitabine Sales (Kg), Revenue (Million US$), Price (USD/g) and Gross Margin (2016-2021)
Table 66. Hikma Capecitabine Product
Table 67. Hikma Recent Developments/Updates
Table 68. Hengrui Medicine Corporation Information
Table 69. Hengrui Medicine Description and Business Overview
Table 70. Hengrui Medicine Capecitabine Sales (Kg), Revenue (Million US$), Price (USD/g) and Gross Margin (2016-2021)
Table 71. Hengrui Medicine Capecitabine Product
Table 72. Hengrui Medicine Recent Developments/Updates
Table 73. Cipla Corporation Information
Table 74. Cipla Description and Business Overview
Table 75. Cipla Capecitabine Sales (Kg), Revenue (Million US$), Price (USD/g) and Gross Margin (2016-2021)
Table 76. Cipla Capecitabine Product
Table 77. Cipla Recent Developments/Updates
Table 78. Reliance Group Corporation Information
Table 79. Reliance Group Description and Business Overview
Table 80. Reliance Group Capecitabine Sales (Kg), Revenue (Million US$), Price (USD/g) and Gross Margin (2016-2021)
Table 81. Reliance Group Capecitabine Product
Table 82. Reliance Group Recent Developments/Updates
Table 83. Hetero Corporation Information
Table 84. Hetero Description and Business Overview
Table 85. Hetero Capecitabine Sales (Kg), Revenue (Million US$), Price (USD/g) and Gross Margin (2016-2021)
Table 86. Hetero Capecitabine Product
Table 87. Hetero Recent Developments/Updates
Table 88. Production Base and Market Concentration Rate of Raw Material
Table 89. Key Suppliers of Raw Materials
Table 90. Capecitabine Distributors List
Table 91. Capecitabine Customers List
Table 92. Capecitabine Market Trends
Table 93. Capecitabine Growth Drivers
Table 94. Capecitabine Market Challenges
Table 95. Capecitabine Market Restraints
Table 96. Global Capecitabine Sales Forecast by Type (2022-2029) & (Kg)
Table 97. Global Capecitabine Sales Market Share Forecast by Type (2022-2029)
Table 98. Global Capecitabine Revenue Forecast by Type (2022-2029) & (US$ Million)
Table 99. Global Capecitabine Revenue Market Share Forecast by Type (2022-2029)
Table 100. Global Capecitabine Sales Forecast by Application (2022-2029) & (Kg)
Table 101. Global Capecitabine Sales Market Share Forecast by Application (2022-2029)
Table 102. Global Capecitabine Revenue Forecast by Application (2022-2029) & (US$ Million)
Table 103. Global Capecitabine Revenue Market Share Forecast by Application (2022-2029)
Table 104. Global Capecitabine Sales Forecast by Region (2022-2029) & (Kg)
Table 105. Global Capecitabine Sales Market Share Forecast by Region (2022-2029)
Table 106. Global Capecitabine Revenue Forecast by Region (2022-2029) & (US$ Million)
Table 107. Global Capecitabine Revenue Market Share Forecast by Region (2022-2029)
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Capecitabine
Figure 2. Global Capecitabine Market Share by Type in 2020 & 2029
Figure 3. 500 mg Product Picture
Figure 4. 150 mg Product Picture
Figure 5. Global Capecitabine Market Share by Application in 2020 & 2029
Figure 6. Breast Cancer
Figure 7. Colorectal Cancer
Figure 8. Stomach Cancer
Figure 9. Global Capecitabine Revenue, (US$ Million), 2016 VS 2021 VS 2029
Figure 10. Global Capecitabine Market Size 2016-2029 (US$ Million)
Figure 11. Global Capecitabine Sales 2016-2029 (Kg)
Figure 12. Global Capecitabine Market Size Market Share by Region: 2016 VS 20210 VS 2029
Figure 13. Capecitabine Sales Share by Manufacturers in 2020
Figure 14. Global Capecitabine Revenue Share by Manufacturers in 2020
Figure 15. The Global 5 and 10 Largest Capecitabine Players: Market Share by Revenue in 2020
Figure 16. Capecitabine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 17. Global Capecitabine Sales Market Share by Region (2016-2021)
Figure 18. Global Capecitabine Sales Market Share by Region in 2020
Figure 19. Global Capecitabine Revenue Market Share by Region (2016-2021)
Figure 20. Global Capecitabine Revenue Market Share by Region in 2020
Figure 21. U.S. Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 22. Canada Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Germany Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. France Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. U.K. Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Italy Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Russia Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. China Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Japan Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. South Korea Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. India Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Australia Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Taiwan Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Indonesia Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Thailand Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Malaysia Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Philippines Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Vietnam Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Mexico Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Brazil Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Argentina Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Turkey Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Saudi Arabia Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. U.A.E Capecitabine Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Sales Market Share of Capecitabine by Type (2016-2021)
Figure 46. Sales Market Share of Capecitabine by Application (2016-2021)
Figure 47. Sales Market Share of Capecitabine by Application in 2020
Figure 48. Revenue Share of Capecitabine by Application (2016-2021)
Figure 49. Revenue Share of Capecitabine by Application in 2020
Figure 50. Manufacturing Cost Structure of Capecitabine
Figure 51. Manufacturing Process Analysis of Capecitabine
Figure 52. Capecitabine Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
The research methodology employed by VICResearch has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of VICResearch. VICResearch’s methodology can be divided into five stages:
Stage 1: Secondary research
The research team first works with magazines, industry trade group, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.
Stage 2: Primary research: interviews with trade sources
After the first stage, the research team conducts large number of face-to-face or telephone interviews with the representative companies operating in the research field. The analysts attempt to obtain a chance to talk with leading players in the field as well as with small companies. The upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers are all included in the interviews. The data gathered during the interview is then carefully checked and compared with the secondary research.
Stage 3: Analysis of the gathered data
The analysis team checks and synthesizes the data gathered during the first two stages. To validate the data, a second series of interviews can be conducted.
Stage 4: Quantitative data
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by VICResearch. The data is based on the estimates obtained during stage 3.
The research team also provides appreciation and analysis of the market and the quantitative data contained in the reports. The data is consequently unique to VICResearch.
Stage 5: Quality control
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the VICResearch’s internal quality process.
Consulting report: +86-15323335301 020-31521856
